Ken Griffin Cara Therapeutics, Inc. Put Options Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q4 2023 Feb 14, 2024	SELL	$0.6 - $1.65 $2,700 - $7,425	-4,500 Reduced 28.13%	11,500 $8,000
Q3 2023 Nov 14, 2023	BUY	$1.67 - $3.33 $11,356 - $22,644	6,800 Added 73.91%	16,000 $26,000
Q2 2023 Aug 14, 2023	SELL	$2.83 - $4.94 $9,056 - $15,808	-3,200 Reduced 25.81%	9,200 $26,000
Q1 2023 May 15, 2023	SELL	$4.89 - $12.27 $41,076 - $103,068	-8,400 Reduced 40.38%	12,400 $60,000
Q4 2022 Feb 14, 2023	BUY	$8.88 - $12.77 $49,728 - $71,512	5,600 Added 36.84%	20,800 $223,000

Q3 2022 Nov 14, 2022	SELL	$8.24 - $12.56 $27,192 - $41,448	-3,300 Reduced 17.84%	15,200 $142,000

102

21.5M

50K

Ticker CARA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,725,900
Market Cap $17.7M
Description
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.